NCT05660473View on ClinicalTrials.gov

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 15, 2027

Study Completion Date

December 30, 2027

Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
DRUG

Vincristine

Anti-tumor alkaloids

DRUG

Daunorubicin

Anthracycline

DRUG

Cyclophosphamide

Alkylating agent

DRUG

Pegaspargase

Polyethylene glycol (PEG) conjugated to L-asparaginase

DRUG

Prednisone

Glucocorticoids

DRUG

Cytarabine

Pyrimidine antimetabolites

DRUG

6-mercaptopurine

Cell cycle-specific antitumor drug

DRUG

Dexamethasone

Glucocorticoids

DRUG

Methotrexate

Antifolate antineoplastic drug

DRUG

Venetoclax

Selective inhibitor of B-cell lymphoma 2 (Bcl-2)

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER